BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Svensson J, Rydén T, Hagmarker L, Hemmingsson J, Wängberg B, Bernhardt P. A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Phys 2016;3:21. [PMID: 27654452 DOI: 10.1186/s40658-016-0157-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Minczeles NS, de Herder WW, Konijnenberg MW, Feelders RA, Brabander T, Hofland J. Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men. Clin Nucl Med 2022;Publish Ahead of Print. [DOI: 10.1097/rlu.0000000000004203] [Reference Citation Analysis]
2 Huizing DMV, de Wit-van der Veen BJ, Verheij M, Stokkel MPM. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res 2018;8:89. [PMID: 30159614 DOI: 10.1186/s13550-018-0443-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
3 Monserrat Fuertes T, González García FM, Peinado Montes MÁ, Domínguez Grande ML, Martín Fernández N, Gómez de Iturriaga Piña A, Mínguez Gabiña P. Description of the methodology for dosimetric quantification in treatments with 177Lu-DOTATATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:167-78. [PMID: 33811003 DOI: 10.1016/j.remn.2021.02.006] [Reference Citation Analysis]
4 Greene L, Srinivas S, Park S, Hatami N, Nobashi T, Baratto L, Toriihara A, Gambhir SS. Role of Imaging in Early-Phase Trials. Novel Designs of Early Phase Trials for Cancer Therapeutics. Elsevier; 2018. pp. 129-49. [DOI: 10.1016/b978-0-12-812512-0.00010-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 de Vries-Huizing DMV, Versleijen MWJ, Sinaasappel M, Walraven I, Geluk-Jonker MM, Tesselaar MET, Hendrikx JJMA, de Wit-van der Veen BJ, Stokkel MPM. Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course. PLoS One 2021;16:e0260073. [PMID: 34793530 DOI: 10.1371/journal.pone.0260073] [Reference Citation Analysis]
6 Hagmarker L, Svensson J, Rydén T, Gjertsson P, Bernhardt P. Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in 177 Lu-DOTATATE Treatments. Cancer Biotherapy and Radiopharmaceuticals 2017;32:335-43. [DOI: 10.1089/cbr.2017.2317] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys 2021;8:78. [PMID: 34773508 DOI: 10.1186/s40658-021-00422-2] [Reference Citation Analysis]
8 Mora-Ramirez E, Santoro L, Cassol E, Ocampo-Ramos JC, Clayton N, Kayal G, Chouaf S, Trauchessec D, Pouget JP, Kotzki PO, Deshayes E, Bardiès M. Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy. Med Phys 2020;47:4602-15. [PMID: 32632928 DOI: 10.1002/mp.14375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, Beauregard JM. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI Phys 2018;5:25. [PMID: 30318563 DOI: 10.1186/s40658-018-0224-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
10 Hagmarker L, Svensson J, Rydén T, van Essen M, Sundlöv A, Gleisner KS, Gjertsson P, Bernhardt P. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. J Nucl Med 2019;60:1406-13. [PMID: 30902877 DOI: 10.2967/jnumed.118.225235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
11 Gosewisch A, Delker A, Tattenberg S, Ilhan H, Todica A, Brosch J, Vomacka L, Brunegraf A, Gildehaus FJ, Ziegler S, Bartenstein P, Böning G. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Res 2018;8:76. [PMID: 30076556 DOI: 10.1186/s13550-018-0427-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
12 Stabin MG, Madsen MT, Zaidi H. Personalized dosimetry is a must for appropriate molecular radiotherapy. Med Phys 2019;46:4713-6. [PMID: 31520420 DOI: 10.1002/mp.13820] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Kovan B, Özkan ZG, Demir B, Tunçman D, Işik EG, Şimşek DH, Büyükkaya F, Türkmen C, Şanli Y. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium-177-DOTATATE. Cancer Biother Radiopharm 2021. [PMID: 34134512 DOI: 10.1089/cbr.2021.0071] [Reference Citation Analysis]
14 Lubberink M, Wilking H, Öst A, Ilan E, Sandström M, Andersson C, Fröss-Baron K, Velikyan I, Sundin A. In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. J Nucl Med 2020;61:1337-40. [PMID: 32005767 DOI: 10.2967/jnumed.119.237818] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, Konijnenberg M, Cremonesi M, Verburg FA, Bernhardt P, Eberlein U, Gear J. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05727-7] [Reference Citation Analysis]
16 Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, Vandenberghe S, Flamen P. A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours. Phys Med 2018;56:41-9. [PMID: 30527088 DOI: 10.1016/j.ejmp.2018.11.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Hallqvist A, Svensson J, Hagmarker L, Marin I, Rydén T, Beauregard JM, Bernhardt P. Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale. Biomedicines 2021;9:1570. [PMID: 34829796 DOI: 10.3390/biomedicines9111570] [Reference Citation Analysis]
18 Gosewisch A, Ilhan H, Tattenberg S, Mairani A, Parodi K, Brosch J, Kaiser L, Gildehaus FJ, Todica A, Ziegler S, Bartenstein P, Böning G. 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT. EJNMMI Res 2019;9:76. [PMID: 31414241 DOI: 10.1186/s13550-019-0548-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Roth D, Gustafsson J, Sundlöv A, Sjögreen Gleisner K. A method for tumor dosimetry based on hybrid planar-SPECT/CT images and semiautomatic segmentation. Med Phys 2018;45:5004-18. [PMID: 30199102 DOI: 10.1002/mp.13178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, Pacilio M, Strigari L, Summers PE, Orecchia R, Grana CM, Botta F. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 2018;45:2426-41. [PMID: 29785514 DOI: 10.1007/s00259-018-4044-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
21 Rydén T, Heydorn Lagerlöf J, Hemmingsson J, Marin I, Svensson J, Båth M, Gjertsson P, Bernhardt P. Fast GPU-based Monte Carlo code for SPECT/CT reconstructions generates improved 177Lu images. EJNMMI Phys 2018;5:1. [PMID: 29302810 DOI: 10.1186/s40658-017-0201-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
22 Garske-Román U, Sandström M, Fröss Baron K, Lundin L, Hellman P, Welin S, Johansson S, Khan T, Lundqvist H, Eriksson B, Sundin A, Granberg D. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging 2018;45:970-88. [PMID: 29497803 DOI: 10.1007/s00259-018-3945-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 18.0] [Reference Citation Analysis]
23 Huizing DMV, Peters SMB, Versleijen MWJ, Martens E, Verheij M, Sinaasappel M, Stokkel MPM, de Wit-van der Veen BJ. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. EJNMMI Phys 2020;7:36. [PMID: 32488632 DOI: 10.1186/s40658-020-00308-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]